Posted by Michael Wonder on 29 Dec 2022
US FDA accepts for review the biologics license application for Pfizer’s investigational pentavalent meningococcal vaccine candidate (MenABCWY) in adolescents
28 December 2022 - Pfizer today announced that the US FDA accepted for review a biologics license application for its investigational pentavalent meningococcal vaccine candidate (MenABCWY).
Pfizer submitted MenABCWY for the prevention of meningococcal disease caused by the most common serogroups in individuals 10 through 25 years of age.
